HMGB1 and familial pancreatic carcinoma: In the current study, TTFields application significantly suppressed c-Myc expression and induced immunogenic cell death (ICD)-characterized by increased calreticulin cell-surface exposure, extracellular ATP secretion, and elevated HMGB1 release-in pancreatic cancer models.